Stella Ilyayeva, MD
Endocrinology, Diabetes & Metabolism · Rego Park, NYNPI 1619082625
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $169,949 of the $219,096 with a category attached, or 77.6%. 60 manufacturers reported payments, led by Amgen at 53.3% of the total. Reporting peaked in 2019 at $85,165 and has fallen 73.8% since, to $22,294 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,523 payments — averaging $143.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$117K
- Boehringer Ingelheim$28K
- Mannkind Corporation$22K
- AstraZeneca$19K
- Merck$8K
- Lilly USA, LLC$5K
- plus $20K from 54 others
What the payments were for
- Consulting fees$5,1632%
- Speaking & faculty fees$169,94978%
- Travel & lodging$7,1233%
- Food & beverage$36,49117%
- Education$3700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$69,151
- EVENITY$37,249
- JARDIANCE$31,312
- FARXIGA$17,809
- AFREZZA$13,403
- STEGLATRO$7,405
- TEPEZZA$6,905
- V-GO$5,771
- Korlym$674
- CeQur Simplicity$476
- Guardian Sensor 3$355
- DEXCOM G7 GSS (161)$255
- Ozempic$250
- XARELTO$250
- Pogo Automatic Blood Glucose Monitoring System$224
- Omnia$147
- DEXCOM STELO GLUCOSE BIOSENSOR$130
- Synthroid$125
- NEXLIZET$125
- NEXLETOL$125
How this compares
$219,096 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 5,520 | $4,219,862 |
| OzempicSemaglutide | 3,061 | $3,237,847 |
| MounjaroTirzepatide | 1,720 | $2,022,249 |
| TrulicityDulaglutide | 1,736 | $1,993,171 |
| JanumetSitagliptin Phos/Metformin Hcl | 1,853 | $1,306,290 |
| TepezzaTeprotumumab-Trbw | 21 | $1,089,946 |
| FarxigaDapagliflozin Propanediol | 1,165 | $909,748 |
| AfrezzaInsulin Regular, Human | 587 | $727,391 |
| JanuviaSitagliptin Phosphate | 877 | $626,451 |
| ProliaDenosumab | 361 | $583,920 |
| GlumetzaMetformin Hcl | 84 | $522,252 |
| Metformin Er GastricMetformin Hcl | 266 | $420,754 |
| JentaduetoLinagliptin/Metformin Hcl | 597 | $373,257 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 519 | $349,142 |
| VascepaIcosapent Ethyl | 814 | $302,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Jentadueto, Tradjenta | $27,802 | $4,855,2526,541 claims |
| Lilly USA, LLCMounjaro, Trulicity | $5,209 | $4,015,4203,456 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $2,588 | $3,547,8183,567 claims |
| MerckJanumet, Januvia, Steglatro | $8,103 | $2,027,0612,949 claims |
| AmgenTepezza, Prolia, Evenity (2 Syringes) | $116,713 | $1,846,958453 claims |
| AstraZenecaFarxiga | $19,221 | $909,7481,165 claims |
| Mannkind CorporationAfrezza | $22,259 | $727,391587 claims |
| AbbVieCreon, Synthroid, Linzess | $1,539 | $273,5382,376 claims |
| BayerKerendia | $704 | $183,401196 claims |
| Aimmune Therapeutics, Inc.Zenpep | $28 | $56,33143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Rego Park
- Maria PenaRego Park$239K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.